{"id":"W4292884011","doi":"10.2217/fon-2022-0595","title":"HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"ca_institutions":"Zymeworks (Canada); Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Trastuzumab; Internal medicine; Chemotherapy; Oncology; Gastroesophageal Junction; Monoclonal antibody; Cancer; Adenocarcinoma; Antibody; Immunology; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001198645,0.0005391653,0.001212089,0.0004947397,0.0003454499,0.0008938258,0.0007193228,0.0008617095,0.003783883],"category_scores_gemma":[0.0004678228,0.0003112205,0.0008631262,0.000347078,0.0007408186,0.0007880672,0.0004282858,0.002227673,0.000593023],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009471893,"about_ca_system_score_gemma":0.001441494,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007270395,"about_ca_topic_score_gemma":0.003951804,"domain_scores_codex":[0.9995878,0.0001571409,0.00003012662,0.00008247671,0.00005157143,0.00009083772],"domain_scores_gemma":[0.9997397,0.0000280716,0.00006295976,0.00001774548,0.00001405637,0.0001374394],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6499197,0.04973606,0.004449927,0.001657971,0.001271162,0.0001908281,0.0002088878,0.002365812,0.06059912,0.001327585,0.002835097,0.2254379],"study_design_scores_gemma":[0.6007178,0.363463,0.01046298,0.0001529552,0.0007725217,0.0002994942,0.00009868766,0.001413688,0.0106792,0.0005525467,0.01133883,0.00004810368],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9821665,0.003887843,0.001090262,0.0006654187,0.0002339925,0.006717302,0.001055004,0.0001158831,0.004067704],"genre_scores_gemma":[0.9855123,0.002279846,0.003464306,0.0009624198,0.0001001945,0.004049222,0.0009383786,0.00002631341,0.002666925],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003783883,"threshold_uncertainty_score":0.01265836,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01669934964258832,"score_gpt":0.2941696805263527,"score_spread":0.2774703308837643,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}